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Hypothesis: Type 2diabetesmellitus (T2DM) and chronic heart failure (CHF) are associatedwith renal dysfunction.
We tested the hypothesis that the degree of renal dysfunction inﬂuences the negative impact on the outcome of
T2DM in patients with CHF and reduced left ventricular ejection fraction (LVEF).
Methods: From November 1, 2009 to December 31, 2012, the “Trieste Registry of CV Diseases” enrolled 19,589
patients. Thosewith diagnosis of CHF and reduced LVEFwere analyzed. The primary end-point was all-causemor-
tality.
Results: 554 patients were selected (73 ± 10 years old, 32% females), 192 had T2DM (35%). During follow-
up (23±11 months), all-cause death occurred in 57 patients (30%)who had T2DMand in 58 (16%, p b 0.001)who
had not; T2DMwas associated with an increased risk of death (adjusted HR 2.55 [95% CI 1.02-6.36], p= 0.04). The
prognostic impact of T2DM was lost when patients were selected according to renal function: adjusted HR
1.44 [0.21-9.93], p= 0.71, in patients with normal renal function, deﬁned as estimated glomerular ﬁltration
rate (eGFR) N60, and adjusted HR 3.37 [0.96-11.80], p = 0.08 in patients with renal dysfunction (eGFR
b 60 ml/min ∗ 1.73 m2). T2DM predicted all-cause mortality only in the subgroup with eGFR between 90
and 30 ml/min ∗ 1.73 m2 (adjusted HR 2.52 [1.01-6.30], p = 0.04).
Conclusions: In patients with CHF and reduced LVEF the prognostic impact of T2DM depends on the degree
of renal dysfunction. Its contribution in all-causemortality risk prediction is limited tomild–moderate renal
dysfunction subgroup, while prognostic power is lost in normal renal function and in severe renal dysfunc-
tion patients.
© 2014 The Authors. Published by Elsevier Ireland Ltd. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/3.0/).1. Introduction
Chronic heart failure (CHF) and chronic renal disease (CKD) often
co-exist and their presence is due to the increasing age of the general
population, the reduction of renal perfusion due to the impairment ofeliability and freedom from bias
Triestina , Via Slataper 9, 34125
35.
o).
land Ltd. This is an open access articlsystolic cardiac performance and the tailored treatment of both condi-
tions [1]. These two syndromes have common predisposing factors
such as hypertension, type 2 diabetesmellitus (T2DM), obesity and ath-
erosclerosis, so that they share the same pathophysiological mecha-
nisms of disease. The negative impact of CKD on clinical outcomes in
patients with CHF is notorious [2–4], and in those patients in whom
CKD coexists with T2DM, the mortality rate is particularly high, above
the entire cardiovascular one [5]. Even T2DM is a well-recognized pre-
dictor of outcome in patients with CHF [4–8]. However, it is not clear
whether its prognostic impact is inﬂuenced in some way or fully inde-
pendent of the grade of CKD in these patients. As an example, we
recently demonstrated that in patients with severe renal dysfunctione under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
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had a paradoxical protective effect on one-year all-cause mortality [9].
Accordingly, we analyzed a large cohort of patients with CHF with the
aim of assessingwhether the degree of CKDmay inﬂuence the prognos-
tic role of T2DM in these patients.
2. Methods
FromNovember 1, 2009 to December 31, 2012, 19,589 patients who
underwent cardiovascular (CV) ambulatory evaluation were included
in the “Trieste Registry of CV Diseases”. Clinical data were derived
from the E-data chart for outpatient clinic (Cardionet®) of CV Center
of Trieste, Italy, and collected in a regional Data Warehouse. Data on
patients with a diagnosis of CHF and reduced left ventricular ejection
fraction (LVEF, deﬁned as values of LVEF b 50%) were analyzed. All pa-
tients gave their consent to this study and the anonymousmanagement
of their individual data. The study protocol was approved by the localTable 1
Main clinical characteristics of the 554 study patients with chronic heart failure and reduced lef
Age is the age of patients at theirﬁrst visit; Female gender (or female) is the percentage of patien
is the percentage of patients with body mass index N 30; History of Hypertension is the percen
Variables Yes
Diabetes
(192 patients)
Clinical
Age (years) 72 ± 9
Female gender (%) 24
Body mass index (kg/m2) 27.1 ± 5.2
Obesity (%) 30
History of hypertension (%) 82
NYHA functional class (1-4) 2.3 ± 0.6
NYHA class 3-4 (%) 31
Atrial ﬁbrillation 42
Ischemic etiology of heart failure 68
Systolic blood pressure (mm Hg) 131 ± 19
Diastolic blood pressure (mm Hg) 77 ± 9
Heart rate (beats/min) 74 ± 16
Laboratory
Hemoglobin (gr/dl) 13.2 ± 1.5
HbA1c (%) 7.2 ± 1.1
Azotemia (mg/dl) 56 ± 32
GFR (ml/min/1.73 m2) 61 ± 25
GFR (class 1-5) 2.7 ± 1.2
GFR b 60 ml/min/1.73 m2 (%) 53
Serum sodium (mEq/l) 140 ± 3
Serum potassium (mEq/l) 2.5 ± 0.6
Echocardiography
LV end-diastolic volume (ml/m2) 75 ± 27
LV end-diastolic volume (ml/m2) 50 ± 22
LV ejection fraction (%) 35 ± 9
LV wall motion score index (1–3) 2.01 ± 0.42
LV relative wall thickness 0.38 ± 0.10
LV mass (height2) 67 ± 20
E/E′ 19.6 ± 10.9
Pulmonary capillary wedge pressure (mm Hg) 26 ± 11
Severe LV diastolic dysfunction (%) 59
Moderate-severe mitral regurgitation (%) 28
Left atrial area (cm2) 29 ± 8
Pulmonary artery systolic pressure (mm Hg) 42 ± 14
Pharmacological treatment
Betablockers (%) 40
ACEi/ARB (%) 64
Diuretics (%) 42
Aldosterone antagonist (%) 32
Digitalis (%) 23
Nitrates (%) 37
Antiplatelets agents (%) 67
Anticoagulant (%) 16
Statins (%) 50institutional review boards. The study protocol conforms to the ethical
guidelines of the Declaration of Helsinki as revised in 2000.
CHF was deﬁned according to the recent guidelines [10]. All
patients underwent a complete echocardiogram where LVEF was
calculated in a biplane mode according to the Simpson's methods.
T2DM was primarily deﬁned as a history of diabetes (self-report
or retinopathy), use of medications to treat T2DM or newly diag-
nosed T2DM deﬁned as fasting blood glucose of 126 mg/dl or non-
fasting blood glucose of 200 mg/dl in the absence of self-report or
medication use.
Renal functionwas expressed as estimated glomerular ﬁltration rate
(eGFR) calculated by the CKD-EPI equation [11]. The study population
was divided in 5 subgroups based on the K/DOQI classiﬁcation: class I
(normal eGFR) = eGFR ≥ 90; class II (mild CKD) = eGFR 60-89; class
III (moderate CKD) = eGFR 30-59; class IV (severe CKD) = eGFR 15-
29; class V (kidney failure) = eGFR b 15 ml/min * 1.73 m2) [12]. All
clinical characteristics of these patients are summarized in Table 1.t ventricular ejection fraction divided according to the presence of type II diabetesmellitus.
ts of female sex; Bodymass index is the ratio betweenweight and height squared; Obesity
tage of patients with hypertension in therapy.
No
Diabetes
(362 patients)
p Total study population
(554 patients)
74 ± 10 0.03 73 ± 10
35 0.009 32
25.9 ± 4.0 0.004 26.3 ± 4.5
17 b0.001 21
67 b0.001 72
2.2 ± 0.6 0.34 2.2 ± 0.6
26 0.41 28
46 0.38 44
56 0.38 61
130 ± 20 0.70 130 ± 20
76 ± 11 0.22 77 ± 11
73 ± 18 0.64 73 ± 17
13.5 ± 1.7 0.16 13.4 ± 1.6
6.3 ± 1.2 0.02 7.0 ± 1.3
52 ± 30 0.16 53 ± 30
64 ± 22 0.31 63 ± 23
2.5 ± 1.2 0.19 2.6 ± 1.2
37 0.01 44
140 ± 3 0.31 140 ± 3
4.4 ± 0.5 0.32 4.4 ± 0.5
77 ± 28 0.39 77 ± 27
51 ± 23 0.65 50 ± 23
36 ± 9 0.29 36 ± 9
2.01 ± 0.41 0.97 2.01 ± 0.42
0.38 ± 0.11 0.47 0.38 ± 0.11
70 ± 21 0.2 69 ± 21
16.8 ± 9.1 0.03 17.8 ± 9.8
23 ± 13 0.03 24 ± 12
46 0.04 50
36 0.14 33
29 ± 8 0.59 29 ± 8
38 ± 14 0.01 40 ± 14
42 0.67 42
61 0.48 62
46 0.27 44
26 0.11 28
19 0.19 20
32 0.31 34
55 0.007 59
21 0.14 19
38 0.006 42
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Fig. 1. Distribution of patients with type 2 diabetes mellitus according to the degree of
renal dysfunction. 0 6 12 18 24 30 36 42
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Fig. 2. All-cause death-free survival in patients with and without type 2 diabetes mellitus.
Kaplan–Meier survival curves are shown and the difference between the two curves was
tested for signiﬁcance by the log-rank test.
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Data are reported as mean values ± 1 standard deviation. Unpaired
Student's test and χ2 statistics were used for descriptive statistics.
Between-group comparisons of continuous and normally distributed
variables were performed by the analysis of variance. Kaplan–Meier
survival curves were performed and the differences were tested for
signiﬁcance by the log-rank test. Log cumulative hazard functions
were also computed by univariate and multivariate Cox proportional
hazards analyses to identify the predictors of all-cause mortality
(primary end-point) and probabilities of event-free survival. In the
ﬁnal model, along with T2DM that was included as a categorical vari-
able, other variables included in multivariate Cox regression models
were selected as possible confounding factors on the basis of their
signiﬁcance in univariate analyses: age, body mass index, systolic
blood pressure, beta-blocker treatment, and NYHA functional class. All
analyses were performed using statistical package SPSS 19.0 (SPSS Inc.
Chicago, Illinois) and statistical signiﬁcance was identiﬁed by two-
tailed p b 0.05.4. Results
The study population consisted of 554 patients whose main clinical
characteristics are shown in Table 1. T2DM was diagnosed in 192 sub-
jects (35% of total study population). Patients who had T2DM were
younger, more frequently male and obese with a higher prevalence of
hypertension and a worse renal function than those who had not.
As far as the echocardiographic parameters are concerned, the for-
mer presented amore severe degree of diastolic dysfunction and higher
pulmonary artery systolic pressure than the latter. Moreover, patients
who had T2DM were treated more aggressively with the use of
anti-platelets and statins than those who had not, while the use of
beta-blockers, ACEi/ARBs, diuretics, aldosterone antagonists, di-
uretics and digitalis was similar in the two groups both when studyTable 2
Cox proportional hazard multivariate analysis for prediction of death for all cause (primary en
Multivariate analysis Dead for all cause
n = 115
(21%)
Alive at f
n = 439
(79%)
Diabetes mellitus 50% 31%
NYHA functional class (1–4) 2.5 ± 0.7 2.1 ± 0.6
Beta-blocker treatment 29 45
Systolic blood pressure (mm Hg) 125 ± 17 132 ± 2
Age (years) 78 ± 8 72 ± 10
Body mass index (kg/height2) 26.6 ± 4.7 26.7 ± 4patients were considered all together, and when divided in various
subgroups according to the degree of CKD. The distribution of pa-
tients with T2DM according to the degree of renal dysfunction is
shown in Fig. 1.
During a follow-up period of 23 ± 11 months, 115 patients died
(21%), 38 of them (7%) within the ﬁrst year of observation. All-cause
death occurred in 57 of 192 patients (30%) with T2DM and in 58 of
362 patients (16%, p b 0.001) without T2DM. As expected, considering
the total study population, Cox regression analysis revealed that T2DM
was associated with an increased risk of death (adjusted HR 2.55 [95%
CI 1.02–6.36], p = 0.04) independently of NYHA class and the lack of
beta-blocker therapy (Table 2, Fig. 2). However, when patients
were grouped according to the absence or presence of renal dys-
function [deﬁned as eGFR b 60 ml/min ∗ 1.73 m2] the prognostic sig-
niﬁcance of T2DMwas lost (Table 3). Notably, T2DM, independently
of NYHA class and beta-blocker therapy, predicted all-cause mortal-
ity in the sub-group of patients with eGFR comprised between 90
and 30 ml/min ∗ 1.73 m2 (adjusted HR 3.37 [95% CI 1.10–10.31],
p = 0.03) (Table 3, Fig. 3).5. Discussion
This study demonstrates that in out-patients with CHF the impact of
T2DMof all-causemortality is strongly inﬂuenced by the degree of CKD.
We found, indeed, that whereas renal function was normal or, on the
opposite side of the spectrum, renal dysfunction was severe, the pres-
ence of T2DM was non-inﬂuential on all-cause mortality. On the con-
trary, T2DM emerged as an independent predictor of adverse events
in patients with mild–moderate CKD. These results are consistent with
data recently reported by our group derived by IN-HFOutcome Registryd-point).
ollow-up HR Conﬁdence intervals p
2.56 1.14–5.72 0.02
2.55 1.33–4.96 0.005
0.42 0.19–0.92 0.03
0 0.98 0.95–1.01 0.09
1.06 0.99–1.14 0.76
.3 1.06 0.99–1.14 0.76
Table 3
Number of events in patientswith andwithout Diabetes and prognostic power of Diabetes on primary end-point (all-causemortality). Analysis in the total population and in the subgroup
with different degree of renal function measured as glomerular ﬁltration rate (CPK-EPI equation).
Number of patients Number of deaths Yes
Diabetes
No
Diabetes
Unadjusted HR
(95% CI)
p Adjusted HR
(95% CI)
p
Total population 554
(100%)
115
(21%)
52/192
(30%)
58/362
(16%)
1.97
(1.36-2.84)
b0.001 2.56
(1.14-5.72)
0.02
GFR N 60 ml/min/1.73/m2 313
(56%)
42
(13%)
16/79
(20%)
26/234
(11%)
2.06
(0.86-4.95)
0.11 0.06
(1.12-3.06)
0.54
GFR b 60 ml/min/1.73/m2 241
(44%)
73
(30%)
46/113
(41%)
27/128
(21%)
2.34
(1.14-4.82)
0.02 2.75
(0.95-7.97)
0.60
GFR between 90 and 30 ml/min/1.73/m2 416
(75%)
86
(21%)
55/158
(35%)
31/258
(12%)
3.20
(1.66-6.10)
b0.001 3.37
(1.10-10.31)
0.03
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an episode of acute heart failure were selected and analyzed. In this
population, we observed that the absence, not the presence of T2DM,
was a predictor of one-year mortality. Fox et al. [13] lately showed
that even in less-suffering patients belonging to general population or
high-risk CV cohorts, the relative risks of mortality outcomes according
to lower eGFR were much the same irrespective of the presence or ab-
sence of T2DM, emphasizing the dominant role of CKD in comparison
with that of T2DM as a predictor of clinical adverse events.
Three different theories might be hypothesized to explain our re-
sults: 1) the possibility that several CHF patients may develop some
protective mechanisms inﬂuencing positively the outcome with a
power that overcomes the negative effect of T2DM itself and/or 2)
the circumstance that the negative prognostic effect of T2DM may
be exhausted in patients who survived both the CHF and the severe
CKD, the two major complications of T2DM and 3) the evidence
that by our approach, we compared subgroups of patients with
T2DM to counterparts without T2DM who belong to the same class
of CKD and, consequently, who have similar contraindications to
the evidence-based heart failure medications (such as ACEi/ARBs,
aldosterone antagonists, diuretics, digitalis) that may inﬂuence
renal function and, even more relevant, morbidity and mortality
[14]. It is well-known, indeed, that the presence of CKD is associated
with underuse or use at very low doses of these pharmacological0 6 12 18 24 30 36 42
Follow-up (months)
0,4
0,5
0,6
0,7
0,8
0,9
1,0
A
ll-cause death-free survival (%
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p = 0.0002
Fig. 3.All-cause death-free survival in subgroups of patientswith andwithout type 2 diabetesm
(left panel) and with eGFR b 30 ml/min/1.73 m2 (right panel). Kaplan–Meier survival curves artherapies proportionally to the degree of CKD itself. So, these com-
pelled behaviors might have a prognostic impact more relevant
than T2DM itself.
Very few data are available on patients with severe renal dysfunc-
tion and CHF due to the exclusion of these patients from randomized
studies [1,15]. Furthermore, the role of CKD on clinical outcomes of pa-
tientswith T2DMwho suffer from CHFhas not been studied speciﬁcally.
These considerations, together with the results of the present study,
clearly suggest the need of analyzing patients with CHF following
criteria that lead to make more homogeneous the study groups
with a particular attention to the small subgroups of patients deﬁned
as “outliers”, who often hold useful information for a better compre-
hension of the pathophysiological mechanisms which originate and
sustain CHF.6. Conclusion
Previous studies conﬁrm that diabetes and renal dysfunction are
predictor factors of increased mortality in patients with acute and
chronic heart failure. Furthermore, none of them analyze whether the
prognostic values of diabetes would inﬂuence the mortality inside the
different classes of renal dysfunction. We analyze this aspect and we
found out that diabetes is a predictor of mortality above all in the0 6 12 18 24 30 36 42
Follow-up (months)
0,3
0,4
0,5
0,6
0,7
0,8
0,9
1,0
Diabetes NO
Diabetes YES
Log rank test
p = 0.64
Subgroup of patients with GFR
lower than 30 ml/min/1.73 m2
ellituswith estimated glomerularﬁltration rate (eGFR) between 90 and30 ml/min/1.73m2
e shown and the differences were tested for signiﬁcance by the log-rank test.
57G. Russo et al. / IJC Metabolic & Endocrine 4 (2014) 53–57mild–moderate dysfunction and its prognostic power was loss in the
lowest class of renal failure.
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